(secondQuint)A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain.

 This is a multicenter, open-label study in patients 40 years and older who are undergoing a surgical procedure.

 Upon meeting all entrance criteria, patients will be administered the first dose of ST 30 mcg and will remain in the study for up to 12 hours for safety and efficacy measurements.

 Patients may receive additional doses of ST 30 mcg as needed for pain management, but no more frequently than every 60 minutes.

.

 A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain@highlight

This is a multicenter, open-label study in patients 40 years and older who are undergoing a surgical procedure.

 Patients may receive one dose of ST 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.

